First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients

Hongyi Chen; Zhicheng Zhang; Li Wang; Zhihua Huang; Fanghua Gong; Xiaodong Li; Yahong Chen; Jinzi J. WU

Chinese adult (18-75 years old in both genders) pneumonia patients with SARS-COV-2 infection confirmed to be positive by RT-PCR; demonstrated respiratory symptoms and imaging-confirmed pneumonia as defined in China National Standards; naïve patients were newly diagnosed patients who never received any antiviral treatments and danoprevir/ritonavir treatment were initiated within 7 days or less from the diagnosis; experienced patients might receive antiviral therapies with dosage and treatment duration recommended by China National Standards [14] ; women and their partners with no planned pregnancy for 6 months after the study and willing to take effective contraceptive measures within 30 days from the first administration of the study drugs; patients agreed that they would not participate in other clinical trials within 30 days from the last administration of the study drugs; patients were willing to sign informed consent form.